AtriCure
ATRC
222 hedge funds and large institutions have $2.22B invested in AtriCure in 2023 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 88 increasing their positions, 74 reducing their positions, and 24 closing their positions.
4,767% more call options, than puts
Call options by funds: $730K | Put options by funds: $15K
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
19% more capital invested
Capital invested by funds: $1.86B → $2.22B (+$362M)
19% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 74
0.75% less ownership
Funds ownership: 96.05% → 95.3% (-0.75%)
1% less funds holding
Funds holding: 224 → 222 (-2)
4% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$13.2M |
| 2 |
JP Morgan Chase
New York
|
+$12.4M |
| 3 |
Millennium Management
New York
|
+$8.77M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$8.47M |
| 5 |
Man Group
London,
United Kingdom
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$9.99M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$8.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$7.69M |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
-$6.83M |
| 5 |
PCM
Peregrine Capital Management
Minneapolis,
Minnesota
|
-$6.7M |
ATRC Hedge Fund Activity: Q2 2023 in Review
222 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in AtriCure (ATRC) for Q2 2023, worth a combined $2.22B — up 19% from $1.86B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATRC and 23 opened new positions — a net loss of 1 holder — while 74 trimmed existing stakes and 88 added.
The largest buyer was Nuveen, adding an estimated $13.2M. The largest seller was Invesco, cutting an estimated $9.99M.
- 222 institutional investors held AtriCure (ATRC) as of Q2 2023, down from 224 in Q1 2023.
- Funds reported $2.22B of AtriCure stock for Q2 2023, up 19% quarter-over-quarter.
- 23 funds opened new AtriCure positions in Q2 2023 and 24 closed out, a net change of -1 holder.
- The largest AtriCure buyer in Q2 2023 was Nuveen, an estimated $13.2M added.
- The largest AtriCure seller in Q2 2023 was Invesco, an estimated $9.99M sold.
Based on aggregated 13F filings for Q2 2023.